Effectiveness of ayurvedic formulation, NAOQ19 along with standard care in the treatment of mild-moderate COVID-19 patients: A double blind, randomized, placebo-controlled, multicentric trial

Medicines in indigenous systems such as Ayurveda have strong antimicrobial activity but double-blind randomized control trials are infrequent in this system of medicine. The efficacy of a new ayurvedic formulation was evaluated during the pandemic. 150 mild-moderate COVID-19 patients were enrolled a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of ayurveda and integrative medicine 2023-11, Vol.14 (6), p.100778-100778, Article 100778
Hauptverfasser: Bhardwaj, Pankaj, Ganapathy, Kalaiselvan, Pathania, Monika, Naveen, K H, Charan, Jaykaran, Dutta, Siddhartha, Gadepalli, Ravisekhar, Srinivasan, Srikanth, Gupta, Manoj Kumar, Goel, Akhil D, Midha, Naresh, Kumar, Bharat, Sharma, Meenakshi, Sharma, Praveen, Banerjee, Mithu, Mitra, Prasenjit, Misra, Sanjeev, V, Vinayagamoorthy, Subramaniant, Girija, R, Praveen, Dhar, Minakshi, Saxena, Vartika, Dhamija, Puneet, Singh, Archana, Subramanian, Saumya, Kanchibhotla, Divya
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Medicines in indigenous systems such as Ayurveda have strong antimicrobial activity but double-blind randomized control trials are infrequent in this system of medicine. The efficacy of a new ayurvedic formulation was evaluated during the pandemic. 150 mild-moderate COVID-19 patients were enrolled and randomized in 1:1 to NAOQ19 and placebo group. RT-PCR was done on Day 3, 5 and 7. CBC, CRP, LFT, and KFT were assessed at baseline and exit. Duration of hospital stay was noted and clinical assessment was also performed. The results demonstrated more people turning RT-PCR negative in the NAOQ19 group compared to the placebo group on day 3 (p-value = 0.033). The mean time duration to turn RT-PCR negative was significantly lower in the NAOQ19 group (4.6 days) compared to placebo group (5.2 days) (p-value = 0.018). There was significant reduction in hospital stay among patients in the NAOQ19 arm who were discharged earlier (5.6 days) compared to placebo group (6.4 days) (p-value = 0.046). Patients in NAOQ19 arm did not show any adverse life-threatening events. The ayurvedic preparation given along with standard of care therapy reduced the duration of hospital stay and there was earlier conversion to RT-PCR negative.The integrated approach can help to reduce patient workload in the hospitals as well as limit the transmission of the virus in the community. CTRI/2021/05/033790.
ISSN:0975-9476
0976-2809
DOI:10.1016/j.jaim.2023.100778